LegoChem Biosciences Inc (141080.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Life Sciences Tools & Services · South Korea · ISIN KR7141080002

Price
63,100.00 KRW
Market cap
2.30 tn KRW
P/E (2025)
–
P/S (2025)
16.23
Dividend yield
0.00 %
Net margin
-52.47 %
Return on equity (ROE)
-13.73 %
Return on assets (ROA)
-10.58 %

LegoChem Biosciences Inc financials

Fiscal year20242025
Revenue125.90 bn KRW141.55 bn KRW
Gross profit109.95 bn KRW126.00 bn KRW
Operating income-20.95 bn KRW-106.49 bn KRW
EBIT9.63 bn KRW-93.01 bn KRW
Net income7.80 bn KRW-74.28 bn KRW
Diluted EPS – continuing operations214.99 KRW-2,040.31 KRW

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About LegoChem Biosciences Inc

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.